Kidney Function in Sickle Cell Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-17

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in kidney function, and to identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function.

"Funding Source - FDA OOPD"

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Screening Patients With Sickle Cell Disease for Kidney Damage

NCT02239016

Sickle Cell Disease

COMPLETED

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271

Sickle Cell Disease Kidney Injury Kidney Diseases +1 more

COMPLETED

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

NCT05214105

Sickle Cell Disease Kidney Diseases, Chronic

RECRUITING

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT00011648

Pulmonary Hypertension Sickle Cell Anemia Sickle Cell Disease

COMPLETED

A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients

NCT01220115

Sickle Cell Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sickle cell disease is a severe monogenic disorder which affects approximately 80,000 patients in the US. It is characterized by a vasculopathy with involvement of multiple organs and resulting in complications such as ischemic stroke, pulmonary hypertension, autosplenectomy, priapism, as well as chronic kidney disease (CKD). Despite the high prevalence of CKD and its known association with increased mortality, the natural history of CKD and the factors associated with changes in kidney function in patients with SCD remain incompletely defined. Furthermore, the available treatment options for albuminuria, an early manifestation of CKD, in patients with SCD are limited. In fact, no controlled studies have confirmed the long-term efficacy of angiotensin-converting enzyme (ACE) inhibitors, the current "standard of care." There is increasing evidence for a contribution of endothelial dysfunction to the pathophysiology of albuminuria in SCD. The association of biomarkers of endothelial function with albuminuria provides opportunities, not only to assess the effect of therapies which improve endothelial function, but also to evaluate the predictive value of these biomarkers for a decline in kidney function. The long-range goal is to develop a model to identify patients at particularly high risk for a decline in kidney function.

In this study, the investigators will evaluate rate of change in kidney function (decline in estimated glomerular filtration rates and increase in albuminuria) and identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function. At the conclusion of this proposed work, the investigators will have an improved understanding of the natural history of CKD in sickle cell anemia. With the limited available therapies for the treatment of albuminuria in SCD and the paucity of data on the long-term efficacy of available pharmacotherapies, identification of biomarkers for the progression of CKD will facilitate the development of treatments which may be more effective than the current "standard of care."

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease Kidney Failure, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age of 18 to 65 years;
2. confirmed diagnosis of sickle cell anemia (HbSS and SB0 thalassemia);
3. non-crisis, "steady state" with no severe pain episodes requiring medical contact during the preceding 4 weeks;
4. ability to understand the requirements of the study and be willing to give informed consent.

Exclusion Criteria

1. bone marrow transplantation;
2. history of long-standing diabetes mellitus with suspicion for diabetic nephropathy as determined by a nephrologist;
3. known diagnosis of hepatitis B or C infection (patients will not be screened specifically for this during the study);
4. known HIV positive (patients will not be screened specifically for this);
5. history of cancer, except non-melanoma skin cancer;
6. pregnant or breastfeeding;
7. connective tissue disease such as SLE;
8. known glomerular disease unrelated to SCD;
9. patients with ESRD on chronic dialysis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No